APi Group Corp
Construction
APi Group Corp (APG) Stock News
The latest APG headlines and market coverage — 4 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
Halper Sadeh LLC is Investigating Whether NEE, CRBG, RMAX, APGE are Obtaining Fair Deals for their Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed mergers and acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers.
- GlobeNewswire Inc.·
Halper Sadeh LLC is Investigating Whether APGE, LPRO, HUN, AVNS are Obtaining Fair Deals for their Shareholders
Investor rights law firm Halper Sadeh LLC is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting competing offers.
- GlobeNewswire Inc.·
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Apogee Therapeutics, Inc. (Nasdaq – APGE), Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG)
Brodsky & Smith law firm has announced investigations into multiple merger transactions, including Apogee Therapeutics (acquired by AbbVie for $135.11/share), Roku (acquired by Fox for $160/share), TruBridge (acquired by Inventurus for $26.25/share), and Organon (acquired by Sun Pharmaceutical for $14/share). The investigations focus on whether the respective boards breached fiduciary duties by failing to conduct fair processes and whether deal consideration provides fair value to shareholders.
- GlobeNewswire Inc.·
Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026
Ascentage Pharma presented clinical data on alrizomadlin (APG-115), an MDM2-p53 inhibitor, for treating pediatric solid tumors at ASCO 2026. The drug showed preliminary antitumor activity with manageable safety profiles as monotherapy and in combination with lisaftoclax, achieving a 23.5% objective response rate in the combination arm. Alrizomadlin was included in China's SPARK Plan for pediatric oncology development.